In order to provide further proof-of-concept that IL-34 inhibition can be used to tackle neurodegenerative disease, it is inevitable to apply other strategies which offer an improved brain penetrance profile, ideally by using small molecule inhibitors, which to date does not exist. Here, IL34 is linked to neurodegenerative disease.